leisure time -WSS

leisure time

author：explore 2025-10-02 20:48:34 - browse：78746

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Why Medicare shouldn’t cover every FDA

hotspot

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Humana’s losses in Medicare Advantage tank its stock

Boston competes with Raleigh

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Medicare drug price negotiation legal challenge met with skepticism

Investment in vaccine development is lagging, report finds

focus

leisure time

knowledge

Virginia high school admissions case could be legal follow

Boston competes with Raleigh

Hepatitis C has a cure — but many Americans still lack access to it

Reconstructing family trees of blood cells may help predict disease

Tori Bowie and the unacceptable rates of Black maternal death

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Anesthesiologist group: stop taking Ozempic before surgery

Why you shouldn’t ask, “What country has the best health care?”

Malaria cases in Florida and Texas: Here’s what you need to know

Pancreatic cancer early detection could be helped by AI

entertainment

FTC sues over Novant Health acquisition of two N.C. hospitals

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Why Medicare shouldn’t cover every FDA

Philips to halt sales of sleep apnea machines in U.S.

New clues to why women have higher risk of autoimmune disorders

Humana’s losses in Medicare Advantage tank its stock

knowledge

hotspot

hotspot

hotspot